164 related articles for article (PubMed ID: 29161979)
1. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
[TBL] [Abstract][Full Text] [Related]
2. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
3. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
[TBL] [Abstract][Full Text] [Related]
5. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
[TBL] [Abstract][Full Text] [Related]
6. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
August KJ; Miller WP; Dalton A; Shinnick S
J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
[TBL] [Abstract][Full Text] [Related]
8. Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review.
Abbott LS; Zakova M; Shaikh F; Shewaramani N; Punnett A; Dupuis LL
Paediatr Drugs; 2015 Aug; 17(4):315-21. PubMed ID: 25862348
[TBL] [Abstract][Full Text] [Related]
9. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
[TBL] [Abstract][Full Text] [Related]
10. The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia: A City-wide Experience.
Alrazzak M; Beaupin LK; Kinyoun P; Barth M
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e16-20. PubMed ID: 26558809
[TBL] [Abstract][Full Text] [Related]
11. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
Sikorska-Fic B; Makowska K; Rokicka-Milewska R
Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
[TBL] [Abstract][Full Text] [Related]
12. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia.
Aldoss I; Douer D; Behrendt CE; Chaudhary P; Mohrbacher A; Vrona J; Pullarkat V
Eur J Haematol; 2016 Apr; 96(4):375-80. PubMed ID: 26095294
[TBL] [Abstract][Full Text] [Related]
13. From the Children's Oncology Group: Evidence-Based Recommendations for PEG-Asparaginase Nurse Monitoring, Hypersensitivity Reaction Management, and Patient/Family Education.
Woods D; Winchester K; Towerman A; Gettinger K; Carey C; Timmermann K; Langley R; Browne E
J Pediatr Oncol Nurs; 2017; 34(6):387-396. PubMed ID: 28602129
[TBL] [Abstract][Full Text] [Related]
14. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Larson RA; Fretzin MH; Dodge RK; Schiffer CA
Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
[TBL] [Abstract][Full Text] [Related]
17. Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
Beaupin LK; Bostrom B; Barth MJ; Franklin I; Jaeger R; Kamath P; Schreiber B; Bleyer A
Leuk Lymphoma; 2017 Apr; 58(4):766-772. PubMed ID: 27643446
[TBL] [Abstract][Full Text] [Related]
18. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
[TBL] [Abstract][Full Text] [Related]
19. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
[TBL] [Abstract][Full Text] [Related]
20. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
